

Multiplex molecular diagnostics: the key for a double-threat respiratory illness season



Each year, respiratory illnesses cause significant disruptions to daily life.



3-5 million


Severe cases of flu globally each year¹



Estimated
380k
flu hospitalizations in the U.S. during the 2019-2020 flu season²




Approximately
1 billion
colds
500 million
non-influenza
respiratory infections



occur annually in the U.S.^{3,4}



COVID-19
has underscored the value of **rapid and comprehensive molecular testing**.
Your ability to quickly and accurately diagnose the cause of infection, particularly among seriously ill patients, is critical.



<p>Reduce time to diagnosis</p> <p>~90 minutes</p> <p>Results from ePlex[®] Respiratory Panel 2 returned in ~90 min</p>	<p>Optimize bed management and more efficient infection control</p> <p>8.4% reduction</p> <p>reduction in hospital admissions⁵</p>	<p>Increase patient satisfaction</p> <p>Less time</p> <p>spent in ER or ICU waiting for test results⁶</p> <p>Reduced fear and uncertainty with a comprehensive diagnosis</p>	<p>Decrease unnecessary antibiotic use</p> <p>1 in 6</p> <p>ER visits for adverse drug events are due to antibiotics⁷</p> <p>Up to 50%</p> <p>of antibiotics prescribed in hospitals are either unnecessary or inappropriate⁸</p>	<p>Diagnose cause of illness with a single test</p> <p>Only 22%</p> <p>of positive test results indicated infection with influenza⁶</p>
---	---	--	--	--

To learn more about multiplex molecular diagnostic testing, visit diagnostics.roche.com/ePlex

1. World Health Organization. (February 2022). Seasonal Influenza Fact Sheet 211. <http://www.who.int/mediacentre/factsheets/fs211/en/>
 2. Centers for Disease Control and Prevention. (February 2022). <https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm>
 3. National Institutes of Health. (February 2022). <https://www.nih.gov/news-events/nih-research-matters/understanding-common-cold-virus#:~:text=People%20in%20the%20United%20States,colds%20are%20caused%20by%20rhinoviruses.>
 4. Fendrick A, et al. (2003) The Economic Burden of Non-Influenza-Related Viral Respiratory Tract Infection in the United States. Arch Intern Med 163(4):487-94.
 5. Weiss, Z.F, et al. Opportunities Revealed for Antimicrobial Stewardship and Clinical Practice with Implementation of a Rapid Respiratory Multiplex Assay. J Clin Micro. 2019; 57(10):e00861-19.
 6. Schreckenberger and McAdam. 2015. Point-Counterpoint: Large Multiplex PCR Panels Should be First Line Test for Detection of Respiratory and Intestinal Pathogens. JCM 53(10):3110-3115
 7. Centers for Disease Control and Prevention. (February 2022). <https://www.cdc.gov/medicationsafety/adverse-drug-events-specific-medicines.html>
 8. Antibiotic resistance threats in the United States, 2013. (February 2022). U.S. Dept. of Health and Human Services. Centers for Disease Control and Prevention. <https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf>

